The Amgen FIRST STEP™ Program is a medical benefit co-pay coupon program to help commercially insured eligible patients with their deductible, co-insurance, and/or co-pay requirements for Neulasta®(pegfilgrastim), Nplate®(romiplostim), XGEVA®(denosumab), and Prolia® (denosumab). 100% of an eligible patient’s combined co-payment, coinsurance or deductible will be covered for the patient’s first dose of the Amgen product covered by the AMGEN FIRST STEP™ Program. For all subsequent doses, Amgen will pay the patient’s combined out-of-pocket co-payment, coinsurance or deductible amount in excess of $25 per dose for a total program benefit up to $5,000 per patient, per 6-month period with the exception of Prolia which will pay up to $1,500 per 6 month period. The 6-month program period runs from January 1 through June 30 and July 1 through December 31.
Eligible patients can be enrolled in the program and receive program benefits across program benefit periods. The $5,000 cap, or $1,500 cap simply restarts on the first day of the new 6-month program period cycle until the patient’s treatment regimen ends or the program is discontinued, whichever is sooner. Starting January 1, eligible patients must re-enroll in the program on an annual basis for benefit coverage of a single course of treatment. Eligible patients may re-enroll at any time a new course of treatments with a covered Amgen product is initiated.
The Amgen FIRST STEP™ Program may help eligible patients with out-of pocket costs associated with Neulasta®, Nplate® , XGEVA®, or Prolia® purchased and administered at a participating clinic or institution. The program does not cover costs associated with a patient visit including physician, staff, or administrative charges associated with administering the applicable Amgen product, or the out-of-pocket costs for Neulasta®, Nplate®, XGEVA®, or Prolia®. purchased at a specialty or retail pharmacy and then administered at a clinic or institution. A clinic or institution must first be enrolled before a patient can participate in this program.
Amgen reserves the right to deny payment under the Amgen FIRST STEP™ Program to anyone deemed ineligible in accordance with the stated criteria. Providers may be obligated under their contracts with payers to disclose acceptance of funds provided through this card for products dispensed to their patients. Providers must not seek reimbursement from any third-party payer for any amount provided by the Amgen FIRST STEP™ Program. Providers may not advertise or otherwise use this card as a means of promoting their services or Amgen products. This offer is not valid in the State of Massachusetts and is void where otherwise prohibited by law. Patients enrolled in Medicare, Medicaid or any other federally funded healthcare program are ineligible for program benefits.
Amgen reserves the right to modify or terminate this program, in whole or in part without notice at any time.
The AMGEN FIRST STEP™ Program is the main umbrella program under which each individual, product-specific-program falls. For easy reference, the product-specific-programs are referred to collectively as the AMGEN FIRST STEP™ Program. All of the AMGEN FIRST STEP™ eligibility requirements, terms, conditions and limitations apply equally to all of the product-specific programs.